The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TNXP Detailed Price Forecast - CNN Money||View TNXP Detailed Summary - Google Finance|
|View TNXP Detailed Summary - Yahoo! Finance||View TNXP Stock Research & Analysis - Zacks.com|
|View TNXP Trends & Analysis - Trade-Ideas||View TNXP Major Holders - Barrons|
|View TNXP Call Transcripts - NASDAQ||View TNXP Breaking News & Analysis - Seeking Alpha|
|View TNXP Annual Report - CompanySpotlight.com||View TNXP OTC Short Report - OTCShortReport.com|
|View TNXP Fundamentals - TradeKing||View TNXP SEC Filings - Bar Chart|
|View Historical Prices for TNXP - The WSJ||View Performance/Total Return for TNXP - Morningstar|
|View the Analyst Estimates for TNXP - MarketWatch||View the Earnings History for TNXP - CNBC|
|View the TNXP Earnings - StockMarketWatch||View TNXP Buy or Sell Recommendations - MacroAxis|
|View the TNXP Bullish Patterns - American Bulls||View TNXP Short Pain Metrics - ShortPainBot.com|
|View TNXP Stock Mentions - StockTwits||View TNXP Stock Mentions - PennyStockTweets|
|View TNXP Stock Mentions - Twitter||View TNXP Investment Forum News - Investor Hub|
|View TNXP Stock Mentions - Yahoo! Message Board||View TNXP Stock Mentions - Seeking Alpha|
|View Insider Transactions for TNXP - SECform4.com||View Insider Transactions for TNXP - Insider Cow|
|View TNXP Major Holdings Summary - CNBC||View Insider Disclosure for TNXP - OTC Markets|
|View Insider Transactions for TNXP - Yahoo! Finance||View Institutional Holdings for TNXP - NASDAQ|
|View TNXP Stock Insight & Charts - FinViz.com||View TNXP Investment Charts - StockCharts.com|
|View TNXP Stock Overview & Charts - BarChart||View TNXP User Generated Charts - Trading View|
Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
Posted on Friday September 07, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately. Dr. Olukotun assumes the seat held by Dr. Ernest Mario, who has stepped down from the position of company director that Dr. Mario has held since 2011. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Olukotun to the Tonix Board, as he brings 30 years of biopharmaceutical operational and leadership experience that will be invaluable to Tonix as we grow the company.
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Posted on Thursday August 30, 2018
NEW YORK, Aug. 30, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences ...
TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented…
Posted on Monday August 27, 2018
On August 21, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced a poster presentation at the 2018 Military Health System Research Symposium that included results from the Phase 3 HONOR trial and retrospective analyses from the HONOR trial and the Phase 2 AtEase trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD). In July 2018, the company announced that the HONOR trial was stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint.
Tonix Pharmaceuticals Announces Director Stepping Down
Posted on Wednesday August 22, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors, effective August 21, 2018. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “On behalf of the Board and management, I would like to thank Sam for his many contributions and dedicated service to Tonix. “It has been my privilege to have worked with the board and management team of Tonix Pharmaceuticals,” said Dr. Saks.